Generation Bio Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Generation Bio in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Generation Bio stock.
View analyst ratings for Generation Bio or view top-rated stocks.

Wall Street analysts have given Generation Bio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Generation Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Generation Bio saw a decrease in short interest in January. As of January 29th, there was short interest totaling 1,630,000 shares, a decrease of 36.8% from the January 14th total of 2,580,000 shares. Based on an average daily trading volume, of 521,900 shares, the short-interest ratio is presently 3.1 days. Approximately 4.9% of the company's stock are short sold.
View Generation Bio's Short Interest.

Generation Bio is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Generation Bio.

Generation Bio Co. (NASDAQ:GBIO) posted its quarterly earnings results on Sunday, November, 15th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.01.
View Generation Bio's earnings history.

6 brokerages have issued twelve-month price targets for Generation Bio's stock. Their forecasts range from $28.00 to $50.00. On average, they anticipate Generation Bio's stock price to reach $38.40 in the next twelve months. This suggests a possible upside of 19.9% from the stock's current price.
View analysts' price targets for Generation Bio or view top-rated stocks among Wall Street analysts.

Some companies that are related to Generation Bio include United Therapeutics (UTHR), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), Sarepta Therapeutics (SRPT), Allakos (ALLK), TG Therapeutics (TGTX), Maravai LifeSciences (MRVI), Evotec (EVTCY), Perrigo (PRGO), Blueprint Medicines (BPMC), Galapagos (GLPG), Turning Point Therapeutics (TPTX), Biohaven Pharmaceutical (BHVN), Atea Pharmaceuticals (AVIR) and Emergent BioSolutions (EBS).
View all of GBIO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Generation Bio investors own include DocuSign (DOCU), NVIDIA (NVDA), Overstock.com (OSTK), The Boeing (BA), Pure Storage (PSTG), Mastercard (MA), QUALCOMM (QCOM), Riot Blockchain (RIOT), Twilio (TWLO) and Enphase Energy (ENPH).

(GBIO) raised $126 million in an IPO on Friday, June 12th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Generation Bio trades on the NASDAQ under the ticker symbol "GBIO."

Generation Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (7.89%), BlackRock Inc. (2.40%), JPMorgan Chase & Co. (1.40%), Victory Capital Management Inc. (1.29%), Harvard Management Co. Inc. (0.94%) and Bank of New York Mellon Corp (0.53%). Company insiders that own Generation Bio stock include Donald William Nicholson, Douglas Kerr, James E Flynn and Matthew Stanton.
View institutional ownership trends for Generation Bio.

GBIO stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., and Wells Fargo & Company MN. Company insiders that have sold Generation Bio company stock in the last year include Douglas Kerr, and Matthew Stanton.
View insider buying and selling activity for Generation Bio or view top insider-selling stocks.

GBIO stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Darwin Global Management Ltd., Price T Rowe Associates Inc. MD, Swiss National Bank, Credit Suisse AG, State of Wisconsin Investment Board, and Harvard Management Co. Inc.. Company insiders that have bought Generation Bio stock in the last two years include Donald William Nicholson, and James E Flynn.
View insider buying and selling activity for Generation Bio or or view top insider-buying stocks.

Shares of GBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GBIO stock can currently be purchased for approximately $32.03.

Generation Bio has a market capitalization of $1.78 billion.

Generation Bio employs 85 workers across the globe.

The official website for Generation Bio is generationbio.com.

Generation Bio is headquartered at 301 BINNEY STREET, CAMBRIDGE MA, 02142.

Generation Bio's mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 857-529-5908 or via email at [email protected]